Skip to main content
Fig. 5 | Journal of Neuroinflammation

Fig. 5

From: Sema4A is implicated in the acceleration of Th17 cell-mediated neuroinflammation in the effector phase

Fig. 5

RRMS patients with high Sema4A levels show more severe disease activity. The cumulative disease-free ratios (a no new or active lesion of MRI, b no increase in EDSS, c no relapse, d NEDA) after the initiation of INF-β treatment are shown. Years after the initiation of IFN-β treatment are indicated on the X axis. 32.1% of patients with low Sema4A significantly achieved NEDA at 5 years, while 12.5% of patients with high Sema4A maintained NEDA status 5 years after the start of IFN-β treatment (d). *P < 0.05

Back to article page
\